Research Article

The Effectiveness of Amantadine in Improving Consciousness in Patients with Acute Brain Injury

Abstract

Background: The improved consciousness level reflects the patient’s recovery following acute brain injury. The medications that can regulate neurotransmitter levels, neural synaptic plasticity, and functional connectivity of consciousness networks might play a crucial role in improving the consciousness status of the patients. Thus, this study aims to evaluate the effectiveness of amantadine in improving consciousness in acute brain injury patients.
Methods: The present quasi-experimental study was performed from 2021 to 2022 after obtaining the necessary permissions from Zahedan University of Medical Sciences, Iran. Eighty patients with acute brain injury who met the study inclusion criteria were recruited and randomized into amantadine and placebo groups. The amantadine group was given a daily dose of 100 mg amantadine tablets, while the placebo group received a gavage of amantadine-like placebo tablets twice daily for 14 days. The consciousness level of patients was measured daily until the outcome (ICU discharge or expiration) was established. Eventually, a comparative data analysis was conducted to determine amantadine's efficacy in enhancing consciousness, reducing mechanical ventilation time, and improving patient outcomes.
Results: The mean GCS score in the amantadine group was 5.5±1.4 on admission and 11.9±3.7 at the end of the study, compared to 6.6±1.5 on admission and 11.8±3 at the end of the study, for the placebo group (p=0.154 and p=0.211, respectively). The mean duration of mechanical was 28.87±11.34 days in the amantadine group and 24.13±14.93 days in the placebo group (P=0.329). Twenty-four patients in the amantadine group were discharged from ICU, and 16 were expired. For the placebo group, 21 patients were discharged from ICU, while 16 were expired (p=0.221). No statistically significant difference was found in any of the measured variables between the two groups.
Conclusion: The results demonstrate that amantadine administration had no statistically significant impact on improving consciousness status and clinical outcomes and reducing mechanical ventilation time in acute brain injury patients.

[1] Alkhachroum A, Eliseyev A, Der-Nigoghossian CA, Rubinos C, Kromm JA, Mathews E, et al. EEG to detect early recovery of consciousness in amantadine-treated acute brain injury patients. J. Neurol. Neurosurg. Psychiatry. 2020; 91(6):675.
[2] McMahon MA, Vargus-Adams JN, Michaud LJ, Bean J. Effects of amantadine in children with impaired consciousness caused by acquired brain injury: a pilot study. Am J Phys Med Rehabil. 2009; 88(7):525-32
[3] Giacino JT, Whyte J, Bagiella E, Kalmar K, Childs N, Khademi A, et al. Placebo-controlled trial of amantadine for severe traumatic brain injury. N Engl J Med. 2012; 366(9):819-26.
[4] Taylor Norman E, Chemali Jessica J, Brown Emery N, Solt K. Activation of D1 Dopamine Receptors Induces Emergence from Isoflurane General Anesthesia. Anesthesiology. 2013; 118(1):30-9.
[5] Abbasivash R, Valizade Hasanloei MA, Kazempour A, Mahdkhah A, Shaaf Ghoreishi MM, Akhavan Masoumi G. The Effect of Oral Administration of Amantadine on Neurological Outcome of Patients With Diffuse Axonal Injury in ICU. J Exp Neurosci. 2019; 13:1179069518824851.
[6] Lu J, Jhou TC, Saper CB. Identification of wake-active dopaminergic neurons in the ventral periaqueductal gray matter. J Neurosci. 2006; 26(1):193-202
[7] Peeters M, Page G, Maloteaux J-M, Hermans E. Hypersensitivity of dopamine transmission in the rat striatum after treatment with the NMDA receptor antagonist amantadine. Brain Res. 2002; 949(1):32-41.
[8] Monti JM, Monti D. The involvement of dopamine in the modulation of sleep and waking. Sleep Med Rev. 2007; 11(2):113-33
[9] Hintze TD, Small CE, Montgomery J, Reveles KR, Hafeez S, Barthol CA. Comparison of Amantadine, Modafinil, and Standard of Care in the Acute Treatment of Disorders of Consciousness After Severe Traumatic Brain Injury. Clin Neuropharmacol. 2022; 45(1):1-6.
[10] Rühl L, Kuramatsu JB, Sembill JA, Kallmünzer B, Madzar D, Gerner ST, et al. Amantadine treatment is associated with improved consciousness in patients with non-traumatic brain injury. J Neurol Neurosurg Psychiatry. 2022; 93(6):582-7.
[11] Thibaut A, Schiff N, Giacino J, Laureys S, Gosseries O. Therapeutic interventions in patients with prolonged disorders of consciousness. Lancet Neurol. 2019; 18(6):600-14
[12] Chen X, Tang C, Zhou H, Li Z. Effect of amantadine on vegetative state after traumatic brain injury: a functional magnetic resonance imaging study. J Int Med Res. 2019;47(2):1015-24.
[13] Schnakers C, Hustinx R, Vandewalle G, Majerus S, Moonen G, Boly M, et al. Measuring the effect of amantadine in chronic anoxic minimally conscious state. J Neurol Neurosurg Psychiatry. 2008; 79(2):225-7
[14] Meythaler JM, Brunner RC, Johnson A, Novack TA. Amantadine to improve neurorecovery in traumatic brain injury-associated diffuse axonal injury: a pilot double-blind randomized trial. J Head Trauma Rehabil. 2002; 17(4):300-13.
[15] Schneider WN, Drew-Cates J, Wong TM, Dombovy ML. Cognitive and behavioural efficacy of amantadine in acute traumatic brain injury: an initial double-blind placebo-controlled study. Brain Inj. 1999; 13(11):863-72.
[16] Hammond FM, Sherer M, Malec JF, Zafonte RD, Whitney M, Bell K, et al. Amantadine Effect on Perceptions of Irritability after Traumatic Brain Injury: Results of the Amantadine Irritability Multisite Study. J Neurotrauma. 2015; 32(16):1230-8.
[17] Ciurleo R, Bramanti P, Calabrò RS. Pharmacotherapy for Disorders of Consciousness: Are ‘Awakening’ Drugs Really a Possibility? Drugs. 2013;73(17):1849-62.
[18] Clauss RP. Neurotransmitters in Coma, Vegetative and Minimally Conscious States, pharmacological interventions. Medical Hypotheses. 2010; 75(3):287-90.
[19] Clauss R. Neurotransmitters in disorders of consciousness and brain damage. Medical hypotheses. 2011;77(2):209-13.
[20] Oliveira L, Fregni F. Pharmacological and electrical stimulation in chronic disorders of consciousness: new insights and future directions. Brain Injury. 2011; 25(4):315-27
[21] Fridman EA, Calvar J, Bonetto M, Gamzu E, Krimchansky BZ, Meli F, et al. Fast awakening from minimally conscious state with apomorphine. Brain injury. 2009; 23(2):172-7
[22] Fridman EA, Krimchansky BZ, Bonetto M, Galperin T, Gamzu ER, Leiguarda RC, et al. Continuous subcutaneous apomorphine for severe disorders of consciousness after traumatic brain injury. Brain injury. 2010; 24(4):636-41
[23] Chang C, Ramphul K. Amantadine. StatPearls [Internet]: StatPearls Publishing; 2022.
[24] Bailey E, Stone T. The mechanism of action of amantadine in Parkinsonism: a review. Arch Int Pharmacodyn Ther. 1975; 216(2):246-62
[25] Horiguchi J, Inami Y, Shoda Ta. Effects of long-term amantadine treatment on clinical symptoms and EEG of a patient in a vegetative state. Clinical neuropharmacology. 1990; 13(1):84-8
[26] Zafonte tw, nancy r. Mann, ross d. Case study: Amantadine: a potential treatment for the minimally conscious state. Brain injury. 1998; 12(7):617-21.
Files
IssueVol 9 No Supp. 2 (2023): Supplement 2 QRcode
SectionResearch Article(s)
DOI https://doi.org/10.18502/aacc.v9i6.14449
Keywords
Acute brain injury Glasgow Coma Scale Amantadine Impaired consciousness level
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Rahat Dahmardeh A, Keykha A, Rezvani Amin M, Khoshfetrat M. The Effectiveness of Amantadine in Improving Consciousness in Patients with Acute Brain Injury. Arch Anesth & Crit Care. 2023;9(Supp. 2):516-521.